Bezafibrate for Hyperfibrinogenemia in Acute Myocardial Infarction
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Introduction: Plasma fibrinogen levels have been identified as an important risk factor for
cardiovascular diseases and could have a prognostic value. Bezafibrate decreases fibrinogen
levels and also the incidence of major cardiovascular events in primary prevention, but its
effects in acute coronary syndrome is unknown.
Hypothesis: Bezafibrate effect over statin therapy reduces fibrinogen concentrations,
inflammatory response and clinical events, in patients with ST segment elevation ACS and
hyperfibrinogenemia.
Methods: In a randomized clinical trial, controlled with conventional therapy. Patients with
ST elevation acute myocardial infarction (STEAMI) and with fibrinogen concentration >500
mg/dl at 72 h of evolution, were randomly assigned to bezafibrate 400 mg/day (group I n=50)
or just conventional therapy (group II n=50). Serum fibrinogen, c reactive protein and
cytokines were measured. Clinical end points were recurrence of angina or infarction, left
ventricular failure, cardiovascular mortality and combined end points during hospitalization.